Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics (PTCT) director reports option exercises and stock sales. A board member exercised stock options on 11/24/2025 and 11/25/2025 at exercise prices of $11.23 and $18.01 per share, converting options into common stock. On the same dates, the director sold shares in multiple transactions at weighted average prices generally between the low $80 and mid $80 per share. After these transactions, the director directly owned 17,451 shares of PTC Therapeutics common stock. The filing states that the trades were carried out under a written Rule 10b5-1 trading plan adopted on March 12, 2025.
PTC Therapeutics director reports stock option exercise and sale. A board member of PTC Therapeutics, Inc. (PTCT) exercised stock options for 10,000 shares of common stock at an exercise price of $51.16 per share on 11/21/2025. On the same day, the director sold 10,000 shares of common stock at a price of $79.50 per share. After these transactions, the director beneficially owned 6,666 shares of PTCT common stock directly. The option exercise was reported as a stock option (right to buy) that was already exercisable and carries an expiration date of 01/28/2030. The filing notes that the transactions were carried out under a pre‑established Rule 10b5‑1 trading plan adopted on March 4, 2025, which is designed to allow trading under predetermined conditions.
PTC Therapeutics director reports charitable stock gift
A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.
PTC Therapeutics executive reports option exercise and share sales
The Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT) reported transactions dated 11/17/2025. The officer exercised a stock option for 2,812 shares of common stock at an exercise price of $25.69 per share, then sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, all under a Rule 10b5-1 trading plan adopted on December 5, 2024.
After these transactions, the officer beneficially owned 103,901 shares of common stock directly and 25,314 stock options with an exercise price of $25.69 expiring on 02/14/2034. The reported option grant was made on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.
PTC Therapeutics (PTCT) filed its Q3 2025 10‑Q, reporting a return to profitability for the quarter and sharply higher year‑to‑date results. Q3 revenue was $211.0 million (vs. $196.8 million a year ago), and net income was $15.9 million (vs. a $106.7 million loss). Diluted EPS was $0.20.
For the first nine months, revenue reached $1.566 billion (vs. $593.6 million), driven by $998.4 million of collaboration and license revenue tied to the Novartis votoplam agreement, with net income of $817.6 million. Cash and cash equivalents were $672.6 million and marketable securities $1.015 billion. The stockholders’ deficit narrowed to $(155.8) million from $(1.10) billion at year‑end.
Product and pipeline updates include FDA approval of Sephience for PKU in July 2025 (and EC authorization in June 2025), EC non‑renewal of Translarna in March 2025 with certain EU country exceptions, and FDA acceptance of the resubmitted Translarna NDA in October 2024. The FDA approved the AADC gene therapy in the U.S. in November 2024 (marketed as Kebilidi). The FDA issued a complete response letter for vatiquinone in August 2025. The Novartis votoplam deal closed in January 2025 with a $1.0 billion upfront payment.
PTC Therapeutics filed an 8-K announcing financial results for the quarter ended September 30, 2025. The full details are provided in a press release furnished as Exhibit 99.1.
The company will host a conference call on November 4, 2025 at 4:30 p.m. Eastern to review the results and other updates. Items 2.02 and 7.01, and Exhibit 99.1, are furnished and not deemed filed under Section 18 of the Exchange Act.
PTC Therapeutics (PTCT) director reported Rule 10b5-1 trades. On 10/30/2025, the insider exercised 12,000 stock options at $38.1 per share and sold 12,000 common shares at $69.5. The filing also lists a separate sale of 3,666 shares at $69.5. After these transactions, the insider reported 6,666 shares held directly.
The trades were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025. The exercised options were currently exercisable and carry an expiration date of January 6, 2032.
PTC Therapeutics insider Mark Elliott Boulding, Executive Vice President and Chief Legal Officer, reported transactions on 10/07/2025 under a written Rule 10b5-1 plan adopted on 12/05/2024. He acquired a stock option for 3,375 shares with an exercise price of $38.10 and an expiration date of 01/06/2032. On the same date he sold a total of 3,375 common shares in three weighted-average-price tranches for aggregate proceeds at weighted prices of $62.89, $63.80, and $64.97 (ranges disclosed per tranche). After these transactions he beneficially owned 103,901 shares.
PTC Therapeutics director Emma Reeve reported multiple transactions on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/04/2025. The filings show a mix of purchases and sales in the issuer's common stock and related stock options. Across the trades on that date the reporting person acquired 10,000 shares and additional option grants totaling 25,562 option rights at exercise prices of $33.02 and $33.63, while executing several sales at weighted average prices in the mid-$60s. The director's reported direct beneficial ownership after the transactions is 10,332 shares.
The transactions were effected pursuant to the 10b5-1 plan and several sale prices are disclosed as weighted averages across multiple trades; detailed per-trade price breakdowns are offered on request to regulators or the issuer.
PTC Therapeutics director Allan Steven Jacobson reported offsetting transactions executed on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/12/2025. He exercised 12,000 stock options with an exercise price of $30.86, receiving 12,000 shares, and simultaneously sold 12,000 shares at $65.00. After the trades his direct holdings changed to 29,451 shares before the sale and 17,451 shares following the sale; the derivative table shows the option became exercisable on 10/03/2025 and expires on 01/03/2026. The form is filed by one reporting person and was signed by an attorney-in-fact on 10/07/2025.